Risk of Post-COVID-19 Conditions Among Adolescents and Adults Who Received Nirmatrelvir-Ritonavir for Acute COVID-19: A Retrospective Cohort Study - Summary - MDSpire
Advertisement
Risk of Post-COVID-19 Conditions Among Adolescents and Adults Who Received Nirmatrelvir-Ritonavir for Acute COVID-19: A Retrospective Cohort Study
To assess the relationship between nirmatrelvir-ritonavir treatment for acute COVID-19 and the risk of post-COVID-19 conditions (PCC) across different age groups (12-17, 18-49, 50-64, ≥65 years).
Key Findings:
Nirmatrelvir-ritonavir treatment reduced PCC risk in adults aged 50-64 years (aHR 0.93, 95% CI 0.92–0.95) and ≥65 years (aHR 0.88, 95% CI 0.87–0.90).
Minimal effect observed in high-risk adults aged 18-49 years (aHR 0.98, 95% CI 0.97–0.99) and no effect in adolescents aged 12-17 years (aHR 1.06, 95% CI 0.66–1.13).
Interpretation:
The study suggests a protective effect of nirmatrelvir-ritonavir against PCC in older adults but not in adolescents, indicating potential benefits of outpatient treatment for reducing severe disease and PCC risk, particularly in older populations.
Limitations:
Retrospective design may introduce bias, potentially affecting the reliability of the findings.
Reliance on claims data may limit the accuracy of PCC diagnosis, as it may not capture all relevant symptoms.
Conclusion:
Outpatient treatment of mild to moderate COVID-19 with nirmatrelvir-ritonavir may help reduce the risk of severe disease and PCC, particularly in older adults.
